Cargando…

Dual-targeting peptides@PMO, a mimetic to the pro-apoptotic protein Smac/DIABLO for selective activation of apoptosis in cancer cells

The refractoriness of tumor cells to apoptosis represents the main mechanism of resistance to chemotherapy. Smac/DIABLO mimetics proved to be effective in overcoming cancer-acquired resistance to apoptosis as a consequence of overexpression of the anti-apoptotic proteins XIAP, cIAP1, and cIAP2. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Giorgio, Eros, Ferino, Annalisa, Huang, Weizhe, Simonetti, Sigrid, Xodo, Luigi, De Marco, Rossella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497945/
https://www.ncbi.nlm.nih.gov/pubmed/37711175
http://dx.doi.org/10.3389/fphar.2023.1237478
_version_ 1785105413668077568
author Di Giorgio, Eros
Ferino, Annalisa
Huang, Weizhe
Simonetti, Sigrid
Xodo, Luigi
De Marco, Rossella
author_facet Di Giorgio, Eros
Ferino, Annalisa
Huang, Weizhe
Simonetti, Sigrid
Xodo, Luigi
De Marco, Rossella
author_sort Di Giorgio, Eros
collection PubMed
description The refractoriness of tumor cells to apoptosis represents the main mechanism of resistance to chemotherapy. Smac/DIABLO mimetics proved to be effective in overcoming cancer-acquired resistance to apoptosis as a consequence of overexpression of the anti-apoptotic proteins XIAP, cIAP1, and cIAP2. In this work, we describe a dual-targeting peptide capable of selectively activating apoptosis in cancer cells. The complex consists of a fluorescent periodic mesoporous organosilica nanoparticle that carries the short sequences of Smac/DIABLO bound to the αvβ3–integrin ligand. The dual-targeting peptide @PMO shows significantly higher toxicity in αvβ3-positive HeLa cells with respect to αvβ3-negative Ht29 cells. @PMO exhibited synergistic effects in combination with oxaliplatin in a panel of αvβ3-positive cancer cells, while its toxicity is overcome by XIAP overexpression or integrin β3 silencing. The successful uptake of the molecule by αvβ3-positive cells makes @PMO promising for the re-sensitization to apoptosis of many cancer types.
format Online
Article
Text
id pubmed-10497945
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104979452023-09-14 Dual-targeting peptides@PMO, a mimetic to the pro-apoptotic protein Smac/DIABLO for selective activation of apoptosis in cancer cells Di Giorgio, Eros Ferino, Annalisa Huang, Weizhe Simonetti, Sigrid Xodo, Luigi De Marco, Rossella Front Pharmacol Pharmacology The refractoriness of tumor cells to apoptosis represents the main mechanism of resistance to chemotherapy. Smac/DIABLO mimetics proved to be effective in overcoming cancer-acquired resistance to apoptosis as a consequence of overexpression of the anti-apoptotic proteins XIAP, cIAP1, and cIAP2. In this work, we describe a dual-targeting peptide capable of selectively activating apoptosis in cancer cells. The complex consists of a fluorescent periodic mesoporous organosilica nanoparticle that carries the short sequences of Smac/DIABLO bound to the αvβ3–integrin ligand. The dual-targeting peptide @PMO shows significantly higher toxicity in αvβ3-positive HeLa cells with respect to αvβ3-negative Ht29 cells. @PMO exhibited synergistic effects in combination with oxaliplatin in a panel of αvβ3-positive cancer cells, while its toxicity is overcome by XIAP overexpression or integrin β3 silencing. The successful uptake of the molecule by αvβ3-positive cells makes @PMO promising for the re-sensitization to apoptosis of many cancer types. Frontiers Media S.A. 2023-08-29 /pmc/articles/PMC10497945/ /pubmed/37711175 http://dx.doi.org/10.3389/fphar.2023.1237478 Text en Copyright © 2023 Di Giorgio, Ferino, Huang, Simonetti, Xodo and De Marco. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Di Giorgio, Eros
Ferino, Annalisa
Huang, Weizhe
Simonetti, Sigrid
Xodo, Luigi
De Marco, Rossella
Dual-targeting peptides@PMO, a mimetic to the pro-apoptotic protein Smac/DIABLO for selective activation of apoptosis in cancer cells
title Dual-targeting peptides@PMO, a mimetic to the pro-apoptotic protein Smac/DIABLO for selective activation of apoptosis in cancer cells
title_full Dual-targeting peptides@PMO, a mimetic to the pro-apoptotic protein Smac/DIABLO for selective activation of apoptosis in cancer cells
title_fullStr Dual-targeting peptides@PMO, a mimetic to the pro-apoptotic protein Smac/DIABLO for selective activation of apoptosis in cancer cells
title_full_unstemmed Dual-targeting peptides@PMO, a mimetic to the pro-apoptotic protein Smac/DIABLO for selective activation of apoptosis in cancer cells
title_short Dual-targeting peptides@PMO, a mimetic to the pro-apoptotic protein Smac/DIABLO for selective activation of apoptosis in cancer cells
title_sort dual-targeting peptides@pmo, a mimetic to the pro-apoptotic protein smac/diablo for selective activation of apoptosis in cancer cells
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497945/
https://www.ncbi.nlm.nih.gov/pubmed/37711175
http://dx.doi.org/10.3389/fphar.2023.1237478
work_keys_str_mv AT digiorgioeros dualtargetingpeptidespmoamimetictotheproapoptoticproteinsmacdiabloforselectiveactivationofapoptosisincancercells
AT ferinoannalisa dualtargetingpeptidespmoamimetictotheproapoptoticproteinsmacdiabloforselectiveactivationofapoptosisincancercells
AT huangweizhe dualtargetingpeptidespmoamimetictotheproapoptoticproteinsmacdiabloforselectiveactivationofapoptosisincancercells
AT simonettisigrid dualtargetingpeptidespmoamimetictotheproapoptoticproteinsmacdiabloforselectiveactivationofapoptosisincancercells
AT xodoluigi dualtargetingpeptidespmoamimetictotheproapoptoticproteinsmacdiabloforselectiveactivationofapoptosisincancercells
AT demarcorossella dualtargetingpeptidespmoamimetictotheproapoptoticproteinsmacdiabloforselectiveactivationofapoptosisincancercells